However, this is a theoretical benefit which has not been validated by large-scale clinical studies, so it should be considered a potential rather than guaranteed effect
But these changes are expected, and theyre biologically driven. Sustaining progress If youre anxious about stopping a GLP-1, ask your doctor if tapering off gradually, taking a lower dose, or using the drug intermittently is a better option (if thats financially possible), Salamon says
You have chronic kidney disease with T2D (FDA approval for Ozempic, January 2025) You have MASH and want the drug with the FDA indication today (Ozempic approval, August 2025) Cost is the primary constraint and compounded semaglutide is cheaper in your market You want an oral option
To put those numbers in human terms, a 220-pound person on the highest dose would lose approximately 50 pounds over the treatment period
Is oral tirzepatide as good as injected